🇺🇸 FDA
Pipeline program

BMN165 20mg/day

165-302

Phase 3 small_molecule completed

Quick answer

BMN165 20mg/day for Phenylketonuria (PKU) is a Phase 3 program (small_molecule) at BioMarin International Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
BioMarin International Limited
Indication
Phenylketonuria (PKU)
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials